See more : Global Water Technologies, Inc. (GWTR) Income Statement Analysis – Financial Results
Complete financial analysis of Accelerate Diagnostics, Inc. (AXDX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Accelerate Diagnostics, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Wuxi Chipown Micro-electronics limited (688508.SS) Income Statement Analysis – Financial Results
- Wuxi ETEK Microelectronics Co.,Ltd. (688601.SS) Income Statement Analysis – Financial Results
- Newmont Corporation (0R28.L) Income Statement Analysis – Financial Results
- Branicks Group AG (DDCCF) Income Statement Analysis – Financial Results
- Origin Property Public Company Limited (ORI-R.BK) Income Statement Analysis – Financial Results
Accelerate Diagnostics, Inc. (AXDX)
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.06M | 12.75M | 11.78M | 11.17M | 9.30M | 5.67M | 4.18M | 246.00K | 147.00K | 122.00K | 48.29K | 236.00K | 1.12M | 2.25M | 1.27M | 475.52K | 183.13K | 212.70K | 502.11K | 118.61K | 850.57K | 653.98K | 855.66K | 1.57M | 2.90M | 7.38M | 2.50M | 2.10M |
| Cost of Revenue | 9.51M | 9.45M | 12.16M | 6.71M | 4.90M | 3.19M | 1.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.65K | 56.65K | 41.60K | 155.51K | 65.63K | 148.54K | 184.25K | 534.64K | 644.01K | 1.23M | 1.15M | 300.00K | 300.00K |
| Gross Profit | 2.55M | 3.30M | -381.00K | 4.46M | 4.40M | 2.48M | 3.18M | 246.00K | 147.00K | 122.00K | 48.29K | 236.00K | 1.12M | 2.25M | 1.27M | 465.87K | 126.48K | 171.10K | 346.60K | 52.98K | 702.03K | 469.73K | 321.02K | 923.38K | 1.67M | 6.23M | 2.20M | 1.80M |
| Gross Profit Ratio | 21.15% | 25.90% | -3.23% | 39.94% | 47.33% | 43.79% | 76.01% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 97.97% | 69.07% | 80.44% | 69.03% | 44.67% | 82.54% | 71.83% | 37.52% | 58.91% | 57.60% | 84.37% | 88.00% | 85.71% |
| Research & Development | 25.35M | 26.92M | 21.94M | 21.26M | 25.35M | 27.64M | 22.30M | 28.20M | 26.02M | 20.05M | 10.67M | 432.00K | 455.00K | 501.60K | 745.93K | 880.98K | 991.58K | 2.16M | 1.30M | 554.42K | 568.87K | 326.58K | 123.49K | 0.00 | 0.00 | 68.77K | 100.00K | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.31M | 2.95M | 810.08K | 869.35K | 919.71K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 709.01K | 1.53M | 997.83K | 956.67K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.32K | 9.62K | 1.40K | 13.28K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 288.86K | 817.35K | 1.20M | 1.29M | 0.00 | 0.00 |
| SG&A | 31.23M | 39.19M | 49.24M | 46.90M | 51.89M | 55.21M | 45.06M | 36.20M | 17.88M | 10.70M | 4.31M | 2.95M | 819.70K | 870.75K | 932.99K | 1.02M | 935.67K | 903.65K | 994.98K | 978.37K | 1.19M | 742.07K | 997.87K | 2.34M | 2.20M | 2.25M | 1.10M | 500.00K |
| Other Expenses | 0.00 | -227.00K | -20.00K | -60.00K | -14.00K | -28.00K | -184.00K | 2.35M | 1.79M | 888.00K | -4.45K | 205.00K | 255.90K | 261.49K | 270.09K | 294.23K | 313.71K | 315.98K | 305.68K | 293.11K | 490.02K | 170.38K | 638.43K | 895.80K | 0.00 | 0.00 | 200.00K | 100.00K |
| Operating Expenses | 56.58M | 66.11M | 71.18M | 68.16M | 77.23M | 82.85M | 67.36M | 66.75M | 45.70M | 31.64M | 15.35M | 3.59M | 1.53M | 1.63M | 1.95M | 2.19M | 2.24M | 3.38M | 2.61M | 1.83M | 2.25M | 1.24M | 1.76M | 3.24M | 2.20M | 2.32M | 1.40M | 600.00K |
| Cost & Expenses | 66.09M | 75.56M | 83.34M | 74.87M | 82.13M | 86.04M | 68.36M | 66.75M | 45.70M | 31.64M | 15.35M | 3.59M | 1.53M | 1.63M | 1.95M | 2.20M | 2.30M | 3.42M | 2.76M | 1.89M | 2.40M | 1.42M | 2.29M | 3.88M | 3.42M | 3.47M | 1.70M | 900.00K |
| Interest Income | 1.12M | 551.00K | 88.00K | 855.00K | 2.81M | 2.85M | 908.00K | 494.00K | 74.00K | 64.00K | 33.49K | 17.00K | 16.09K | 6.05K | 18.33K | 63.08K | 0.00 | 0.00 | 0.00 | 64.26K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 7.74M | 3.77M | 15.55M | 15.55M | 14.26M | 10.11M | 0.00 | 23.00K | 23.00K | 7.00K | 0.00 | 1.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.25M | 3.00M | 2.52M | 3.00M | 2.60M | 2.56M | 2.20M | 2.35M | 1.79M | 888.00K | 362.50K | 205.00K | 255.90K | 261.49K | 270.09K | 294.23K | 313.71K | 315.98K | 305.68K | 282.79K | 293.32K | 170.38K | 638.43K | 895.80K | 702.53K | 328.01K | 200.00K | 100.00K |
| EBITDA | -49.77M | -55.80M | -59.59M | -59.66M | -67.56M | -75.44M | -61.34M | -64.15M | -43.68M | -30.10M | -14.92M | -3.15M | -153.53K | 873.28K | -409.03K | -1.43M | -1.80M | -2.71M | -1.95M | -1.49M | -1.64M | -598.92K | -800.34K | -1.42M | 175.64K | 4.24M | 1.00M | 1.30M |
| EBITDA Ratio | -412.73% | -466.44% | -585.42% | -536.57% | -725.33% | -1,322.59% | -1,534.76% | -25,876.42% | -29,716.33% | -25,050.82% | -30,911.59% | -498.73% | -14.99% | 37.82% | -28.00% | -298.12% | -1,026.29% | -1,354.58% | -391.97% | -1,255.86% | -129.90% | -69.93% | 20.13% | -108.49% | 6.06% | 57.43% | 28.00% | 61.90% |
| Operating Income | -54.03M | -62.81M | -71.56M | -63.70M | -72.83M | -80.37M | -64.18M | -66.50M | -45.55M | -31.52M | -15.31M | -5.35M | -409.43K | 611.79K | -679.12K | -1.73M | -2.11M | -3.20M | -2.26M | -1.77M | -1.55M | -769.30K | -1.44M | -2.32M | -526.89K | 3.91M | 800.00K | 1.20M |
| Operating Income Ratio | -448.03% | -492.51% | -607.37% | -570.53% | -783.38% | -1,417.44% | -1,536.56% | -27,032.93% | -30,985.71% | -25,833.61% | -31,709.35% | -2,267.80% | -36.52% | 27.24% | -53.48% | -363.31% | -1,154.63% | -1,506.59% | -449.89% | -1,494.69% | -181.83% | -117.63% | -168.15% | -147.83% | -18.18% | 52.99% | 32.00% | 57.14% |
| Total Other Income/Expenses | -6.74M | 235.00K | -6.10M | -14.50M | -11.59M | -7.75M | 649.00K | 394.00K | 51.00K | -470.00K | 29.00K | 41.28K | 30.66K | 29.95K | -53.41K | 47.29K | 190.24K | 173.90K | 168.15K | 74.09K | 151.34K | 50.54K | -426.14K | 861.08K | 565.94K | 536.88K | 400.00K | -1.20M |
| Income Before Tax | -60.77M | -62.57M | -77.66M | -78.20M | -84.42M | -88.12M | -63.53M | -66.11M | -45.50M | -31.46M | -15.28M | -5.31M | -378.76K | 641.75K | -714.20K | -1.68M | -1.92M | -3.03M | -2.09M | -1.70M | -1.40M | -718.76K | -1.86M | -1.46M | 39.05K | 4.45M | 1.20M | 1.10M |
| Income Before Tax Ratio | -503.92% | -490.67% | -659.12% | -700.43% | -907.99% | -1,554.06% | -1,521.02% | -26,872.76% | -30,951.02% | -25,786.89% | -31,649.21% | -2,250.42% | -33.78% | 28.58% | -56.24% | -353.37% | -1,050.75% | -1,424.83% | -416.40% | -1,432.23% | -164.04% | -109.91% | -217.95% | -92.89% | 1.35% | 60.26% | 48.00% | 52.38% |
| Income Tax Expense | 850.00K | -77.00K | 45.00K | 5.00K | -111.00K | 211.00K | -651.00K | 267.00K | 74.00K | -527.00K | -22.13K | 1.96M | 378.76K | -641.75K | 714.20K | -47.29K | -190.24K | -173.90K | -168.15K | -789.40K | -19.43K | -318.03K | -318.19K | -533.46K | 31.38K | 1.57M | 200.00K | -1.10M |
| Net Income | -61.62M | -62.49M | -77.70M | -78.21M | -84.31M | -88.33M | -62.88M | -66.37M | -45.50M | -30.93M | -15.28M | -5.31M | -378.76K | 641.75K | -714.20K | -1.68M | -1.92M | -3.03M | -2.09M | -909.42K | -1.38M | -400.73K | -1.55M | -922.54K | 70.43K | 2.88M | 1.00M | 1.10M |
| Net Income Ratio | -510.97% | -490.06% | -659.50% | -700.47% | -906.80% | -1,557.78% | -1,505.43% | -26,981.30% | -30,951.02% | -25,354.92% | -31,649.21% | -2,250.42% | -33.78% | 28.58% | -56.24% | -353.37% | -1,050.75% | -1,424.83% | -416.40% | -766.71% | -161.75% | -61.28% | -180.76% | -58.86% | 2.43% | 39.00% | 40.00% | 52.38% |
| EPS | -4.94 | -7.61 | -12.59 | -13.96 | -15.47 | -16.21 | -11.63 | -12.94 | -10.11 | -7.09 | -4.06 | -4.26 | -0.35 | 0.60 | -0.70 | -1.67 | -1.93 | -3.04 | -2.10 | -0.91 | -1.45 | -0.48 | -2.02 | -1.19 | 0.10 | 3.80 | 1.50 | 8.80 |
| EPS Diluted | -4.94 | -7.61 | -12.59 | -13.96 | -15.47 | -16.21 | -11.63 | -12.94 | -10.11 | -7.09 | -4.06 | -4.26 | -0.35 | 0.60 | -0.70 | -1.67 | -1.93 | -3.04 | -2.10 | -0.91 | -1.45 | -0.48 | -2.01 | -1.19 | 0.10 | 3.50 | 1.20 | 6.80 |
| Weighted Avg Shares Out | 12.48M | 8.22M | 6.17M | 5.60M | 5.45M | 5.45M | 5.41M | 5.13M | 4.50M | 4.36M | 3.76M | 1.25M | 1.08M | 1.04M | 1.02M | 1.01M | 996.70K | 996.70K | 996.12K | 996.12K | 951.06K | 836.30K | 766.80K | 776.71K | 782.19K | 761.05K | 666.67K | 549.30K |
| Weighted Avg Shares Out (Dil) | 12.48M | 8.22M | 6.17M | 5.60M | 5.45M | 5.45M | 5.41M | 5.13M | 4.50M | 4.36M | 3.76M | 1.25M | 1.08M | 1.04M | 1.02M | 1.01M | 996.70K | 996.70K | 996.12K | 996.12K | 951.06K | 836.30K | 767.98K | 776.71K | 803.65K | 812.50K | 833.33K | 549.30K |
Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2023 Financial Results
TUCSON, Ariz. , March 28, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and year ended December 31, 2023.
Accelerate Diagnostics Scheduled Call to Review 2023 Fourth Quarter and Full Year Results.
TUCSON, Ariz. , March 7, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, March 28, 2024, at 4:30 p.m.
Accelerate Diagnostics Announces Pricing of Approximately $15 Million Public Offering and Private Placement
TUCSON, Ariz. , Jan. 19, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) (the "Company") today announced the pricing of an underwritten public offering consisting of 6,860,659 units, each consisting of one share of common stock and one warrant to...
Accelerate Diagnostics Announces Launch of Proposed Public Offering
TUCSON, Ariz. , Jan. 16, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) (the "Company") today announced the launch of a proposed underwritten public offering of 4,500,000 units, each consisting of one share of common stock and one warrant to...
Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2023 Results
TUCSON, Ariz. , Jan. 7, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) (Accelerate), an in vitro diagnostics company dedicated to providing services that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections, today announced...
Accelerate Diagnostics (AXDX) Expands in In Vitro Diagnostics
Accelerate Diagnostics' (AXDX) Arc system eliminates the need for overnight culture incubation, drastically reducing the wait time for identification results.
Accelerate Diagnostics Announces Collaboration for the Use of the Arc™ System in Combination With Bruker´s MALDI Biotyper®
Working together to bring rapid, automated microbial identification directly from positive blood culture samples TUCSON, Ariz. , Nov. 27, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an innovator of rapid in vitro diagnostics in microbiology, announced the signing of...
Accelerate Diagnostics (AXDX) Loses -25.65% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Accelerate Diagnostics (AXDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Accelerate Diagnostics, Inc. (AXDX) Q3 2023 Earnings Call Transcript
Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Laura Pierson - IR Officer Jack Phillips - President & Chief Executive Officer David Patience - Chief Financial Officer Conference Call Participants...
Accelerate Diagnostics Scheduled Call to Review 2023 Third Quarter Results.
TUCSON, Ariz. , Oct. 30, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, November 9, 2023, at 4:30 p.m.
Source: https://incomestatements.info
Category: Stock Reports